HF
PMCB icon

HRT Financial’s PharmaCyte Biotech PMCB Stock Holding History

HRT Financial’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16K Sell
24,741
-158,060
-86% -$121K ﹤0.01% 3593
2025
Q4 		$132K Buy
+182,801
New +$165K ﹤0.01% 2735

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

HRT Financial's PMCB Position: Q1 2026 in Review

HRT Financial reduced its PharmaCyte Biotech (PMCB) stake by 86% in Q1 2026, selling an estimated $121K and leaving 24,741 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #3593.

HRT Financial first reported a position in PMCB in Q4 2025 and has held it in 2 quarters since. The position peaked at $132K in Q4 2025. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • HRT Financial held 24,741 shares of PharmaCyte Biotech worth $16K as of Q1 2026.
  • HRT Financial sold 158,060 PharmaCyte Biotech shares in Q1 2026, an estimated $121K.
  • PharmaCyte Biotech made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3593 holding.
  • HRT Financial first reported a position in PharmaCyte Biotech in Q4 2025 and has held it in 2 quarters since.
  • HRT Financial's PharmaCyte Biotech position peaked at $132K in Q4 2025.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.